StockWatch
·
Medical/Dental Instruments
Quarterly ResultAug 11, 2026, 07:51 AM

Neuronetics Q2 Revenue Up 9.1% to $41.6M; Adjusted EBITDA Turns Positive

AI Summary

Neuronetics reported strong second-quarter 2026 financial results, with total revenue increasing 9.1% to $41.6 million and Adjusted EBITDA turning positive at $0.3 million, a significant improvement from a $5.6 million loss in the prior year. The company also reduced its net loss to $3.4 million and improved its gross margin to 51.1%. Additionally, Neuronetics strengthened its leadership team with key appointments and promotions, and provided updated full-year 2026 guidance reflecting improved profitability metrics.

Key Highlights

  • Nir Naor appointed EVP, CFO; Cory Anderson promoted to EVP/GM Greenbrook; Rob Greene appointed SVP, Sales.
  • Adjusted EBITDA turned positive at $0.3 million in Q2 2026, up from a $5.6 million loss in Q2 2025.
  • Total revenue increased 9.1% to $41.6 million in Q2 2026 compared to Q2 2025.
  • Greenbrook revenue grew 16.8% to $26.9 million in Q2 2026.
  • Net loss significantly reduced to $3.4 million ($0.05 per share) from $10.1 million ($0.15 per share).
  • Gross margin improved to 51.1% in Q2 2026 from 46.6% in Q2 2025.
  • Full-year 2026 revenue guidance set between $160 million and $164 million.
  • Full-year 2026 operating expenses (less stock-based compensation) expected between $91 million and $96 million.